Maggie L. Shaw

Research presented at the 2024 European Society of Cardiology Congress explored gender-based care and outcomes disparities, with potential implications for health care policy and equitable care of women and men in secondary disease prevention.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this second episode, we speak with Rebekah Sedlock, DSW, LCSW, and Mandy Fauble, PhD, LCSW.

At the 2024 European Society of Cardiology Congress (ESC), key research in cardiology care included studies conducted on cardiovascular disease risk among women, cardiac distress and smoking, and lipoprotein(a).

This interview accompanies the first podcast in our National Recovery Month series with Michael Lynch, MD, attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In this first episode, we speak with Michael Lynch, MD, associate professor of emergency medicine at the University of Pittsburgh and an attending emergency physician and medical toxicologist at the University of Pittsburgh Medical Center.

Finerenone's approval by the FDA to treat type 2 diabetes–associated chronic kidney disease was supported by data from the phase 2 FIDELIO-DKD trial; now, the results of FINEARTS-HF show real-world application for patients living with heart failure with preserved ejection fraction or mildly reduced ejection fraction.

The obesity epidemic is a global crisis, with experts from around the world emphasizing the importance of short-term strategies, long-term solutions, and multidisciplinary collaboration as they advocate for the heart health of their patients.

At the 25th International AIDS Conference, Emmanuel Nazaire Essam, MD, MPH, presented the analysis, "Medicaid Insurance Expansion and Its Association With HIV Outcomes in Nebraska, USA: An Observational Prospective Cohort Study."

David Thompson, PhD, Queen’s University Belfast, expands on previous research he conducted that calls for cardiovascular health care providers to actively address care inequities evident in practice and policy.

A joint session from the European Society of Cardiology and the World Heart Federation examined the impact of noise, climate change, and air pollution on cardiovascular disease.

Pregnant and postpartum women who have cardiovascular (CV) disease represent a high-risk group of patients who require specialized care and intense monitoring for optimal health of them and their baby.

New STEP-HFpEF findings presented at this year’s European Society of Cardiology Congress add to the many accolades this glucagon-like peptide-1 receptor agonist has already received for the numerous benefits it can produce among patients living with heart failure with preserved ejection fraction.

This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody.

In part 1 of our interview with Leland Metheny, MD, he explained how a new triple-target chimeric antigen receptor (CAR) T-cell therapy works in multiple myeloma.

The European Society of Cardiology (ESC) Congress 2024 will take place in London, England, August 30 to September 2.

Also known as coal workers’ pneumoconiosis, black lung disease (or miner’s lung) is typically the result of inhaling coal dust for many years that causes scarring in the lungs and makes breathing increasingly difficult. The prevalence of black lung has been on the rise in the US.

Leland Metheny, MD, is lead investigator for the Phase 1 BAFF CAR T clinical trial, which is evaluating the safety and effectiveness of a novel approach to chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM) that targets 3 receptors on cancer cells and uses electroporation vs the typical lentiviral vector delivery.

In part 1 of our interview with David P. Carbone, MD, PhD, The Ohio State University, he addressed why it is important to conduct biomarker testing in both lung cancer overall and non–small cell lung cancer more specifically.

These study authors hope their findings will inform future research on gastrointestinal stromal tumors (GIST) and close care gaps for minority patient populations.

At AIDS 2024 in July, Kelly Dyer, MD, Perelman School of Medicine, presented research findings from an investigation at the intersection of health equity, substance use detox, infectious disease screening, and patient harm reduction.

To continue the response they experienced with a first autologous stem‐cell transplant (ASCT) for their multiple myeloma, patients in this analysis received a second ASCT, with French investigators evaluating their outcomes.

Adverse outcomes in the aftermath of the COVID-19 pandemic continue to be evaluated as they pertain to social determinants of health, with these authors investigating improvements in food hardship among families participating in the Supplemental Nutrition Assistance Program (SNAP).

CDC data from 2021 show the lifetime cost of treating syphilis to be $1190.

Jennifer Cocohoba, PharmD, MAS, AAHIVP, University of California, San Francisco, School of Pharmacy, discusses the benefits of pharmacy-administered long-acting injectable antiretroviral therapy for HIV and patient attitudes toward pharmacy-administered treatment.

Rhabdomyosarcoma, a common form of soft tissue sarcoma in pediatric patients with outcomes that have improved through research, is rare among older patients, who also have significantly poorer outcomes.

This investigation was conducted among older, frail patients, a population typically underrepresented in clinical trials.

Patients who have comorbid relapsed/refractory multiple myeloma (RRMM) and advanced chronic kidney disease (CKD) are often excluded from clinical trials, leaving treatment gaps for these high-risk patients.

A trio of posters presented at AIDS 2024, the 25th International AIDS Conference, explored widespread disparities in access to pre-exposure prophylaxis (PrEP) and how to make access more equitable, both globally and locally.

For the recent AIDS 2024 conference, we spoke with Nishita Dsouza, PhD, MPH, Columbia University School of Social Work Social Intervention Group, who presented research on HIV and sexually transmitted infection prevention among Black women with criminal legal system involvement.

In part 1 of our interview with Anna Sureda, MD, PhD, president of the European Group for Blood and Marrow Transplantation, she summarized the current treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and follicular lymphoma (FL).